Loading clinical trials...

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | Clinical Trials | Clareo Health

COMPLETEDPhase 3NCT01626456

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.

Lead sponsor: Alkermes, Inc.•25 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212 · Schizophrenia

RECRUITINGNA

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

NCT06003036 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

NCT05240976 · Schizophrenia

RECRUITINGNA

Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study

NCT06745479 · Schizophrenia, Schizoaffective Disorder, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 25, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment478

Start dateJun 2012

Last updatedSep 25, 2018

Condition

Schizophrenia

Locations shown

Alkermes Investigational Site

Little Rock, Arkansas

Alkermes Investigational Site

Little Rock, Arkansas

Alkermes Investigational Site

Springdale, Arkansas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 25, 2018Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

Synbiotic Compound to Reduce Symptoms of Schizophrenia

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study

Trial snapshot

Condition

Locations shown

For caregivers